{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 470476685
<!-- Monoclonal antibody data -->
| type = mab
| mab_type = Fab
| source = zu/o
| target = [[Integrin]] α<sub>IIb</sub>β<sub>3</sub>
<!-- Clinical data -->
| tradename =  
| pregnancy_AU =  
| pregnancy_US =  
| pregnancy_category =  
| legal_AU =  
| legal_CA =  
| legal_UK =  
| legal_US =  
| legal_status =  
| routes_of_administration =  
<!-- Pharmacokinetic data -->
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =  
<!-- Identifiers -->
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = none
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 339086-80-5
| ATC_prefix = none
| ATC_suffix =  
| PubChem =  
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =  
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = R34T642CGV
<!-- Chemical data -->
| C=2107 | H=3252 | N=562 | O=673 | S=12
| molecular_weight = 47.6 kg/mol
}}

'''Tadocizumab''' is a [[humanized antibody|humanized]] [[monoclonal antibody]] that acts on the cardiovascular system.<ref name="USAN">[http://www.ama-assn.org/ama1/pub/upload/mm/365/tadocizumab.pdf Statement On A Nonproprietary Name Adopted By The USAN Council - Tadocizumab], ''American Medical Association''.</ref> It binds to [[integrin]] α<sub>IIb</sub>β<sub>3</sub>, a [[fibrinogen]] and [[fibronectin]] [[receptor (biochemistry)|receptor]] found on [[platelet]]s.<ref name=lodish>Molecular cell biology. Lodish, Harvey F. 5. ed. : – New York : W. H. Freeman and Co., 2003, 973 s. b ill. {{ISBN|0-7167-4366-3}}</ref>

The drug is designed for the treatment of patients undergoing [[percutaneous coronary intervention]]s. It was developed by [[Yamanouchi Pharma America|Yamanōchi Pharma America]], Inc.<ref name="USAN" />

== References ==
<references/>

{{Monoclonals for bone, musculoskeletal, circulatory, and neurologic systems}}

[[Category:Monoclonal antibodies]]


{{monoclonal-antibody-stub}}
{{blood-drug-stub}}